Cargando…
Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma
BACKGROUND: The evidence of prognostic factors and individualized surveillance strategies for upper tract urothelial carcinoma are still weak. OBJECTIVES: To evaluate whether the history of previous malignancy (HPM) affects the oncological outcomes of upper tract urothelial carcinoma (UTUC). METHODS...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061966/ https://www.ncbi.nlm.nih.gov/pubmed/36991375 http://dx.doi.org/10.1186/s12894-023-01206-9 |
_version_ | 1785017399981899776 |
---|---|
author | Zhao, Hongda Liu, Kang Giannakopoulos, Stilianos Yuruk, Emrah De Naeyer, Geert Álvarez-Maestro, Mario Ng, Chi-Fai Laguna, Pilar De La Rosette, Jean Yuen-Chun Teoh, Jeremy |
author_facet | Zhao, Hongda Liu, Kang Giannakopoulos, Stilianos Yuruk, Emrah De Naeyer, Geert Álvarez-Maestro, Mario Ng, Chi-Fai Laguna, Pilar De La Rosette, Jean Yuen-Chun Teoh, Jeremy |
author_sort | Zhao, Hongda |
collection | PubMed |
description | BACKGROUND: The evidence of prognostic factors and individualized surveillance strategies for upper tract urothelial carcinoma are still weak. OBJECTIVES: To evaluate whether the history of previous malignancy (HPM) affects the oncological outcomes of upper tract urothelial carcinoma (UTUC). METHODS: The CROES-UTUC registry is an international, observational, multicenter cohort study on patients diagnosed with UTUC. Patient and disease characteristics from 2380 patients with UTUC were collected. The primary outcome of this study was recurrence-free survival. Kaplan-Meier and multivariate Cox regression analyses were performed by stratifying patients according to their HPM. RESULTS: A total of 996 patients were included in this study. With a median recurrence-free survival time of 7.2 months and a median follow-up time of 9.2 months, 19.5% of patients had disease recurrence. The recurrence-free survival rate in the HPM group was 75.7%, which was significantly lower than non-HPM group (82.7%, P = 0.012). Kaplan-Meier analyses also showed that HPM could increase the risk of upper tract recurrence (P = 0.048). Furthermore, patients with a history of non-urothelial cancers had a higher risk of intravesical recurrence (P = 0.003), and patients with a history of urothelial cancers had a higher risk of upper tract recurrence (P = 0.015). Upon multivariate Cox regression analysis, the history of non-urothelial cancer was a risk factor for intravesical recurrence (P = 0.004), and the history of urothelial cancer was a risk factor for upper tract recurrence (P = 0.006). CONCLUSION: Both previous non-urothelial and urothelial malignancy could increase the risk of tumor recurrence. But different cancer types may increase different sites’ risk of tumor recurrence for patients with UTUC. According to present study, more personalized follow-up plans and active treatment strategies should be considered for UTUC patients. |
format | Online Article Text |
id | pubmed-10061966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100619662023-03-31 Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma Zhao, Hongda Liu, Kang Giannakopoulos, Stilianos Yuruk, Emrah De Naeyer, Geert Álvarez-Maestro, Mario Ng, Chi-Fai Laguna, Pilar De La Rosette, Jean Yuen-Chun Teoh, Jeremy BMC Urol Research BACKGROUND: The evidence of prognostic factors and individualized surveillance strategies for upper tract urothelial carcinoma are still weak. OBJECTIVES: To evaluate whether the history of previous malignancy (HPM) affects the oncological outcomes of upper tract urothelial carcinoma (UTUC). METHODS: The CROES-UTUC registry is an international, observational, multicenter cohort study on patients diagnosed with UTUC. Patient and disease characteristics from 2380 patients with UTUC were collected. The primary outcome of this study was recurrence-free survival. Kaplan-Meier and multivariate Cox regression analyses were performed by stratifying patients according to their HPM. RESULTS: A total of 996 patients were included in this study. With a median recurrence-free survival time of 7.2 months and a median follow-up time of 9.2 months, 19.5% of patients had disease recurrence. The recurrence-free survival rate in the HPM group was 75.7%, which was significantly lower than non-HPM group (82.7%, P = 0.012). Kaplan-Meier analyses also showed that HPM could increase the risk of upper tract recurrence (P = 0.048). Furthermore, patients with a history of non-urothelial cancers had a higher risk of intravesical recurrence (P = 0.003), and patients with a history of urothelial cancers had a higher risk of upper tract recurrence (P = 0.015). Upon multivariate Cox regression analysis, the history of non-urothelial cancer was a risk factor for intravesical recurrence (P = 0.004), and the history of urothelial cancer was a risk factor for upper tract recurrence (P = 0.006). CONCLUSION: Both previous non-urothelial and urothelial malignancy could increase the risk of tumor recurrence. But different cancer types may increase different sites’ risk of tumor recurrence for patients with UTUC. According to present study, more personalized follow-up plans and active treatment strategies should be considered for UTUC patients. BioMed Central 2023-03-29 /pmc/articles/PMC10061966/ /pubmed/36991375 http://dx.doi.org/10.1186/s12894-023-01206-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhao, Hongda Liu, Kang Giannakopoulos, Stilianos Yuruk, Emrah De Naeyer, Geert Álvarez-Maestro, Mario Ng, Chi-Fai Laguna, Pilar De La Rosette, Jean Yuen-Chun Teoh, Jeremy Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma |
title | Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma |
title_full | Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma |
title_fullStr | Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma |
title_full_unstemmed | Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma |
title_short | Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma |
title_sort | impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061966/ https://www.ncbi.nlm.nih.gov/pubmed/36991375 http://dx.doi.org/10.1186/s12894-023-01206-9 |
work_keys_str_mv | AT zhaohongda impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT liukang impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT giannakopoulosstilianos impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT yurukemrah impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT denaeyergeert impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT alvarezmaestromario impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT ngchifai impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT lagunapilar impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT delarosettejean impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma AT yuenchunteohjeremy impactofpreviousmalignancyatdiagnosisononcologicaloutcomesofuppertracturothelialcarcinoma |